Breast cancer study halted

Jun 20, 2007

The U.S. National Cancer Institute halted a $100 million study of drugs designed to prevent breast cancer in women at risk for the disease.

The study couldn't be justified amid questions of cost, safety and overall benefit, the institute announced Tuesday.

The dangers of introducing these drugs, with their many known side effects, outweighs their potential," the institute said.

While proponents argued the study was crucial to determining the best drugs to prevent breast cancer, other advocacy groups called for more research to better identify women who would benefit most.

The study would have tested a new generation of drugs known as aromatase inhibitors, The Washington Post reported Wednesday. Under the study, about 12,800 women in the United States and Canada would have received raloxifene or the aromatase inhibitor letrozole.

About 180,000 American women are diagnosed with breast cancer each year and about 40,000 die from the disease, making breast cancer the second most common cancer in women.

Copyright 2007 by United Press International

Explore further: SLNB doesn't up survival in melanoma arising in head, neck

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Putting the brakes on cancer

Dec 19, 2014

A study led by the University of Dundee, in collaboration with researchers at our University, has uncovered an important role played by a tumour suppressor gene, helping scientists to better understand how ...

Peanut component linked to cancer spread

Dec 19, 2014

Scientists at the University of Liverpool have found that a component of peanuts could encourage the spread and survival of cancer cells in the body.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.